Immatics N.V. (IMTX)
4.58
-0.19 (-3.98%)
At close: Feb 20, 2025, 3:59 PM
4.60
0.33%
After-hours: Feb 20, 2025, 06:43 PM EST
undefined% (undefined)
| Bid | 4.6 |
| Market Cap | 547.25M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.64 |
| PE Ratio (ttm) | -7.16 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 4.67 |
| Volume | 1,066,315 |
| Avg. Volume (20D) | 929,469 |
| Open | 4.77 |
| Previous Close | 4.77 |
| Day's Range | 4.51 - 4.83 |
| 52-Week Range | 4.51 - 13.77 |
| Beta | undefined |
About IMTX
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 12, 2018
Employees 572
Stock Exchange NASDAQ
Ticker Symbol IMTX
Website https://www.immatics.com
Analyst Forecast
According to 4 analyst ratings, the average rating for IMTX stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 248.96% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Immatics N.V. is scheduled to release its earnings on Mar 20, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-15.54%
Immatics shares are trading lower after the compan...
Unlock content with
Pro Subscription
11 months ago
-5.89%
Immatics shares are trading lower after the company reported a year-over-year decrease in Q4 financial results.
